First US Patient Enrolled in SELUTION SLR IDE Peripheral Study

The first US patient has been enrolled in the FDA SELUTION4BTK (Below-the-Knee) clinical trial evaluating SELUTION SLR™, MedAlliance’s novel sirolimus-eluting balloon. This milestone follows Investigational Device Exemption (IDE) approval in the US in May 2022, with enrollment of the first patient occurring in Germany one week after approval.   “We are very excited to finally […]

thaipr.net

24 ส.ค. 65

Prominent ophthalmologist will guide Turn Bio’s search for therapies to cure eye diseases

Albert Wu, MD, PhD, a recognized advocate of using stem cell therapy to treat eye conditions, will advise company’s development of ocular tissue rejuvenation therapeutics Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure untreatable, age-related conditions, today announced that Albert Wu, MD, PhD, will oversee its development of ophthalmic therapeutic products as […]

thaipr.net

23 ส.ค. 65

Menarini Group’s Elacestrant Marketing Authorization Application Accepted for Review by the European Medicines Agency (EMA) for the Treatment of ER+/HER2- Advanced or Metastatic Breast Cancer

Elacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from second-line (2L) and third-line (3L) ER+/HER2- advanced or metastatic breast cancer in the European Union Submission supported by results from the pivotal Phase 3 EMERALD study showing a statistically significant difference in the efficacy in favor […]

thaipr.net

22 ส.ค. 65

AMETEK Thailand Opens New Office and Centre of Excellence to Provide Customers in Southeast Asia with AMETEK’s latest Technology Solutions

AMETEK Thailand is pleased to announce that it has opened a new, state-of-the-art facility in a convenient location in Bangkok that will provide enhanced support for customers throughout the Southeast Asia region. AMETEK Thailand began operations in 2017 and continues to play an important role within AMETEK’s Southeast Asia’s ecosystem. The move to a new […]

thaipr.net

17 ส.ค. 65

Kronos Bio and Invivoscribe Partner on Companion Diagnostic for Use with Entospletinib, Kronos Bio’s Investigational Compound Being Developed for Patients with AML

Companion diagnostic would be used following potential regulatory approval of entospletinib to screen for NPM1 mutation present in approximately one-third of all patients with AML Entospletinib is currently being studied in the Phase 3 AGILITY registrational study, with data anticipated in second half of 2023 Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming […]

thaipr.net

17 ส.ค. 65
1 66 67 68 69 70 133